Iterum Therapeutics rises on patent wins, UTI drug launch progress

** Shares of Iterum Therapeutics ITRM rise 2.1% to 69 cents

** ITRM launched its new oral antibiotic, Orlynvah, for treating urinary tract infection across select U.S. markets in August

** Company says physicians have begun writing prescriptions and interest is expanding beyond initial targets

** ITRM also says it secured new intellectual property in two markets — China granted patent covering combination of sulopenem etzadroxil, probenecid and valproic acid, effective through March 2041

** Mexico issued patent for bilayer tablet of sulopenem etzadroxil and probenecid, effective through December 2039

** Including session's move, ITRM shares down 60.6% YTD